Last $3.11 USD
Change Today -0.07 / -2.20%
Volume 74.9K
CYTR On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 9:58 AM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

cytrx corp (CYTR) Snapshot

Open
$3.16
Previous Close
$3.18
Day High
$3.18
Day Low
$3.10
52 Week High
01/30/14 - $8.35
52 Week Low
11/7/13 - $2.00
Market Cap
173.4M
Average Volume 10 Days
688.1K
EPS TTM
$-1.10
Shares Outstanding
55.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYTRX CORP (CYTR)

Related News

No related news articles were found.

cytrx corp (CYTR) Related Businessweek News

No Related Businessweek News Found

cytrx corp (CYTR) Details

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate includes aldoxorubicin that has completed Phase IIb clinical trial as a first-line therapy for soft tissue sarcomas; and has initiated an international Phase II clinical trial in patients with late-stage glioblastoma multiforme, and a Phase II clinical trial in HIV-related Kaposi’s sarcoma. It also develops aldoxorubicin, which is in Phase Ib/II clinical trial primarily in the same indication, a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and is in Phase IIb pharmacokinetics clinical trial in patients with metastatic solid tumors. In addition, the company has evaluated a drug candidate bafetinib, in the ENABLE Phase II clinical trial in high-risk B-cell chronic lymphocytic leukemia. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

cytrx corp (CYTR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.0M
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $450.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $825.0K
Senior Vice President of Legal Affairs, Gener...
Total Annual Compensation: $500.0K
Senior Vice President of Drug Development
Total Annual Compensation: $450.0K
Compensation as of Fiscal Year 2013.

cytrx corp (CYTR) Key Developments

CytRx Corporation Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

CytRx Corporation reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss before other income was $13,337,004 against $6,397,174 a year ago. Net loss was $15,719,473 against $3,423,142 a year ago. Basic and diluted net loss per share was $0.28 against $0.11 a year ago. For the six months, the company reported loss before other income was $23,455,926 against $11,403,258 a year ago. Net loss was $11,054,955 against $10,287,251 a year ago. Basic and diluted net loss per share was $0.21 against $0.34 a year ago.

CytRx Corporation(NasdaqCM:CYTR) added to Russell 2000 Index

CytRx Corporation will be added to the Russell 2000 Index.

CytRx Corporation(NasdaqCM:CYTR) added to Russell 3000 Index

CytRx Corporation will be added to the Russell 3000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTR:US $3.11 USD -0.07

CYTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYTR.
View Industry Companies
 

Industry Analysis

CYTR

Industry Average

Valuation CYTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,770.5x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 748.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTRX CORP, please visit www.cytrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.